Tasquinimod – Enthralling Advancement in Prostate Cancer Treatment

Specialists from the Johns Hopkins, Duke Univ. and Roswell Park Cancer Inst. have made major progress in prostate cancer treatment after a scientific study conducted on two hundred patients found that the blood vessel obstructing medication known as tasquinimod slackened the rate at which the condition progressed.

Tasquinimod is additionally dubbed as the angiogenesis-resistant medication which wrings out blood circulation to the prostate tumors by hampering growth of novel blood vessels. All tumors require extensive nets of blood vessels for supplying nutrient forms.

The multi-center studies conducted at 7 institutes inclusive of John Hopkins, registered people with prostate cancer among whom the condition had metastasized. They were given a single, day-to-day tablet tasquinimod to be taken for 4-weeks. Subsequent to 6 months, fifty-seven percent of the males who took the pill had no kind of advancement in their condition in comparison to thirty-three percent of those who took the placebo. On the whole, this medication appeared to add about twelve weeks of advancement-free time period wherein the condition did not aggravate.

The most commonly experienced side-effects were gastro-intestinal issues, weariness, bone aches and in atypical scenarios, occurrence of cardiac attack, DVT (deep vein thrombosis) and stroke.

Dr. Michael Carducci, Prof. from the Johns Hopkins Kimmel Cancer Center who is slated to helm the third phase of a global clinical trial of the medication, stated that on the basis of such outcomes, it is believed that moving ahead with the Phase-three of the studies is logical. He added that after having explored the medication as a sole agent, the medication might be studied in combo strategies alongside other drugs for enhancing potency of prostate cancer treatment.

Studies that lead to tasquinimod started in the initial part of the nineties when John Isaacs, Prof from John Hopkins uncovered that a medication known as linomide that had been evaluated for treating MS (multiple sclerosis) constricted blood circulation in prostate tumors. But, the medication’s heart side-effects were observed to be quite lethal to human beings hence John Isaacs collaborated along with pharmaceuticals firm Active Biotech recognized tasquinimod for scientific evaluation subsequent to probing for medicines analogous to linomide having similar blood vessel feat yet with lesser toxic effects.

Isaac stated that tasquinimod functions by halting novel vessels from developing around the tumor, however not causing disappearance of existent vascular form.

The notion for angiogenesis-resistant medications for prostate cancer treatment is not preventing tumor development but instead stabilizing the condition.